臺灣人文及社會科學引文索引資料庫系統

:::

詳目顯示

回上一頁
第 1 筆 / 總合 1 筆   第一頁 上一頁 下一頁 最後一頁
/1頁
題名：The Prevalence of KRAS Gene Mutation in Colorectal Cancer Patients with Epidermal Growth Factor Receptor Expression
書刊名：健康管理學刊
作者：范紀鎮／孔建民
作者(外文)：Fan, Chi-chen／Kung, Chien-min
出版日期：2014
卷期：12:2
頁次：頁30-40
主題關鍵詞：結腸直腸癌；標靶藥物治療；KRAS；Colorectal cancer；Targeted drug therapy；EGFR；KRAS
原始連結：連回原系統網址new window
相關次數：
  • 被引用次數被引用次數:期刊(0) 博士論文(0) 專書(0) 專書論文(0)
  • 排除自我引用排除自我引用:0
  • 共同引用共同引用:0
  • 點閱點閱:36
標靶藥物療法通常用於治療結腸直腸癌患者。臨床上，結腸直腸癌組織KRAS基因突變狀態可以決定是否能夠接受對抗上皮細胞生長因子受體（epidermal growth factor receptor, EGFR）之標靶藥物治療的選擇之一。本研究要探討臺灣目前在上皮細胞生長因子受體陽性的結腸直腸癌組織中，KRAS基因突變的盛行率。分析在臺北馬偕醫院已接受治療的164例結腸直腸癌患者（平均年齡61.80±12.78年）。癌瘤組織經免疫化學染色法測定後，選出48例癌瘤組織中EGFR表現陽性樣本，再經桑格（Sanger）定序法分析癌瘤組織中KRAS基因突變狀態。結果在48例癌瘤組織樣本中發現有高達50%之KRAS基因在密碼子12和13上出現突變現象，並且有41.67%是發生在轉移性結腸直腸癌患者組織上。KRAS基因密碼子12的突變率有75.00%，特別是甘氨酸轉成天門冬氨酸（G12D，50.00%）和甘氨酸轉成纈氨酸（G12V，12.50%）。KRAS基因密碼子13突變率有25.00%，主要是甘氨酸轉成天門冬氨酸（G13D，25.00%）。本研究發現有高的KRAS基因突變率出現在EGFR表現陽性的結腸直腸癌組織中。
Anti-epidermal growth factor receptor targeted therapy is typically used to treat colorectal cancer (CRC). The KRAS gene status is one of eligible situations for treating CRC patients with targeting drugs. This study was to clarify the recent prevalence of KRAS gene mutation in CRC patients with epidermal growth factor receptor (EGFR) expression in Taiwan. One hundred and sixty-four patients (mean age, 61.80±12.78 years) who suffered from CRC were enrolled in this study at Mackay Memorial Hospital in Taiwan. Among those CRC paraffin-embedded tissues, 48 subjects with EGFR expression were detected by immunohistochemical method, and those Kirsten RAS (KRAS) gene were amplified using the Sanger sequencing method. The KRAS mutations in codons 12 and 13 were found in 50.00% of all EGFR-expressing CRC patients, and in 41.67% of metastatic CRC patients. The most frequent mutations were those on codon 12 (75.00%), especially glycine-to-aspartate (G12D, 50.00%) and glycine-to-valine (G12V, 12.50%) mutations. A 25.00% mutation on codon 13 was mostly glycine-to-aspartate (G13D, 25.00%). This study identified a high frequency of KRAS somatic mutation in CRC with EGFR expressed patients.
期刊論文
1.Allegra, C. J.、Schilsky, R. L.(2009)。America Society of Clinical Oncology Provisional Opinion: Testing for KRAS Gene Mutations in Patients with Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy。Journal of Clinical Oncology，27，2091-2096。  new window
2.Amado, R. G.、Wolf, M.、Peeters, M.(2008)。Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer。Journal of Clinical Oncology，26，1626-1634。  new window
3.Amador, M. L.、Hidalgo, M.(2004)。Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer。Clinical Colorectal Cancer，4，51-62。  new window
4.Andreyev, H. J.、Norman, A. R.、Cunningham, D.(2001)。Kirsten ras mutations in patients with colorectal cancer: the "RASCAL II" study。British Journal of Cancer，85，692-696。  new window
5.Bazan, V.、Migliavacca, M.、Zanna, I.(2002)。Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous phenotype。Annals of Oncology，13，1438-1446。  new window
6.Benvenuti, S.、Sartore-Bianchi, A.、Di Nicolantonio, F.(2007)。Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies。Cancer Resarch，67，2643-2648。  new window
7.Bond, J. H.(2000)。Polyp guideline: diagnosis, treatment, and surveillance for patients with colorectal polyps. Practice Parameters Committee of the American College of Gastroenterology。The American Journal of Gastroenterology，95(11)，3053-3063。  new window
8.Bos, J. L.(1989)。Ras oncogenes in human cancer: a review。Cancer Resarch，49，4682-4689。  new window
9.Bos, J. L.、Fearon, E. R.、Hamilton, S. R.(1987)。Prevalence of Ras mutations in human colorectal cancers。Nature，327，293-297。  new window
10.Chen, C. J.、You, S. L.、Lin, L. H.(2002)。Cancer Epidemiology and Control in Taiwan: a Brief Review。Japanese Journal of Clinical Oncology，32(Supplement 1)，66-81。  new window
11.Chung, K. Y.、Shia, J.、Kemeny, N. E.(2005)。Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry。Journal of Clinical Oncology，23，1803-1810。  new window
12.Cooley, E. K.、McPhee, J. T.、Simons, J. P.(2009)。Colorectal neoplasia screening before age 50? Current epidemiologic trends in the United States。Diseases of the Colon and Rectum，52(2)，222-229。  new window
13.Cunningham, D.、Humblet, Y.、Siena, S.(2004)。CetuximabMonotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer。The New England Journal of Medicine，351，337-345。  new window
14.Fakih, M.、Wong, R.(2010)。Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer。Current Oncology，17(1)，3-17。  new window
15.Fatima, A. Haggar、Boushey, R. P.(2009)。Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors。Clinics in Colon and Rectal Surgery，22，191-197。  new window
16.Frattini, M.、Saletti, P.、Romagnani, E.(2007)。PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients。British Journal of Cancer，97，1139-1145。  new window
17.Hawkins, N. J.、Ward, R. L.(2001)。Sporadic colorectal cancer with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas。Journal of the National Cancer Institute，93，1307-1313。  new window
18.Heinemann, V.、Stintzing, S.、Kirchner, T.(2009)。Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treatedwith monoclonal antibodies directed against the EGFR。Cancer Treatment Reviews，35，262-271。  new window
19.Jemal, A.、Bray, F.、Center, M. M.(2011)。Global cancer statistics。Ca-A Cancer Journal For Clinicians，61，69-90。  new window
20.Kuan, C. T.、Wikstrand, C. J.、Bigner, D. D.(2001)。EGF mutant receptor vIII as a molecular target in cancer therapy。Endocrine-Related Cancer，8，83-96。  new window
21.Levine, J. S.、Ahnen, D. J.(2006)。Clinical practice. Adenomatous polyps of the colon。The New England Journal of Medicine，355(24)，2551-2557。  new window
22.Lièvre, A.、Bachet, J. B.、Boige, V.(2008)。KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab。Journal of Clinical Oncology，26，374-379。  new window
23.Malapelle, U.、Bellevicine, C.、Salatiello, M.(2012)。Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective。Journal of Clinical Pathology，65，940-944。  new window
24.Malumbres, M.、Barbacid, M.(2003)。RAS oncogenes: the first 30 years。Nature Reviews Cancer，3，459-465。  new window
25.Milano, G.、Etienne-Grimaldi, M. C.、Dahan, L.(2008)。Epidermal growth factor receptor (EGFR) status and K-ras mutations in colorectal cancer。Annals of Oncology，19，2033-2038。  new window
26.Molinari, F.、Martin, V.、Saletti, P.(2009)。Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant。British Journal of Cancer，100，1087-1094。  new window
27.Overman, M. J.、Hoff, P. M.(2007)。EGFR-targeted therapies in colorectal cancer。Diseases of the Colon and Rectum，50，1259-1270。  new window
28.Patil, D. T.、Fraser, C. R.、Plesec, T. P.(2010)。K-RAS testing and its importance in colorectal cancer。Current Oncology Reports，12，160-167。  new window
29.Phipps, A. I.、Buchanan, D. D.、Makar, K. W.(2013)。KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers。British Journal of Cancer，108，1757-1764。  new window
30.Pignone, M.、Saha, S.、Hoerger, T.(2002)。Cost-Effectiveness Analyses of Colorectal Cancer Screening: A Systematic Review for the U.S. Preventive Services Task Force。Annals of Internal Medicine，137，96-104。  new window
31.Rodríguez, J.、Viúdez, A.、Ponz-Sarvisé, M.(2010)。Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab。Critical Reviews in Oncology/Hematology，74，193-202。  new window
32.Schlessinger, J.(2000)。Cell signaling by receptor tyrosine kinases。Cell，103，211-225。  new window
33.Selby, J. V.、Friedman, G. D.、Quesenberry, C. P. J.(1992)。A case control study of screening sigmoidoscopy and mortality from colorectal cancer。The New England Journal of Medicine，326，653-657。  new window
34.Shellnut, J. K.、Wasvary, H. J.、Grodsky, M. B.(2010)。Evaluating the age distribution of patients with colorectal cancer: Are the United States Preventative Services Task Force Guidelines for colorectal cancer screening appropriate?。Diseases of the Colon and Rectum，53，5-8。  new window
35.Solassol, J.、Ramos, J.、Crapez, E.(2011)。KRAS Mutation Detection in Paired Frozen and Formalin-Fixed Paraffin-Embedded (FFPE) Colorectal Cancer Tissues。International Journal of Molecular Sciences，12，3191-3204。  new window
36.Su, S. Y.、Huang, J. Y.、Jian, Z. H.、Ho, C. C.、Lung, C. C.、Liaw, Y. P.(2012)。Mortality of colorectal cancer in Taiwan, 1971-2010: temporal changes and age-period-cohort analysis。International Journal of Colorectal Disease，27，1665-1672。  new window
37.Sung, J. J. Y.、Lau, J. Y. W.、Goh, K. L.(2008)。Asia Pacific consensus recommendations for colorectal cancer screening。Gut，57，1166-1176。  new window
38.Van, C. E.、Köhne, C. H.、Láng, I.(2011)。Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status。Journal of Clinical Oncology，29，2011-2019。  new window
39.Vigil, D.、Cherfils, J.、Rossman, K. L.(2010)。Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy。Nature Reviews Cancer，10，842-857。  new window
40.Williams, J. P.、Stewart, T.、Li, B.(2006)。The retinoblastoma protein is required for Ras-induced oncogenic transformation。Molecular and Cellular Biology，26，1170-1182。  new window
41.Yee, Y. K.、Tan, V. P.、Chan, P.(2009)。Epidemiology of colorectal cancer in Asia。Journal of Gastroenterology and Hepatology，24，1810-1816。  new window
42.Yokota, T.(2012)。Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?。Anti-Cancer Agents in Medicinal Chemistry，12，163-171。  new window
43.Zouhairi, M. E.、Charabaty, A.、Pishvaian, M. J.(2011)。Molecularly Targeted Therapy for Metastatic Colon Cancer: Proven Treatments and Promising New Agents。Gastrointestinal Cancer Research，4，15-21。  new window
44.Bardelli, A.、Siena, S.(2010)。Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer。Journal of Clinical Oncology，28，1254-1261。  new window
圖書
1.Dept. of Health(2009)。Cancer registry annual report (2006)。Taiwan：ROC。  new window
2.Frederick, L. G.、April, G. F.、Daniel, G. H.(2002)。AJCC Cancer Staging Handbook。  new window
3.American Cancer Society。Colorectal Cancer facts and figures 2011-2013。Atlanta：American Cancer Society。  new window
其他
1.Engstrom, P. F.，Arnoletti, J. P.。NCCN Clinical Practice Guidelines in Oncology，http://www.nccn.org/professionals/physician_gls/f_guidelines.asp。  new window
2.World Health Organization。World Health Statistics Annual，Geneva, Switzerland。，http://wwwdepdb.iarc.fr/who/menu.htm， 2008/05/21。  new window
3.International Agency for Research on Cancer.(20101024)。GLOBOCAN 2008：Cancer Incidence and Mortality Worldwide in 2008.，http://globocan.iarc.fr/factsheets/populations/factsheet.asp?Uno=900#KEY。  new window
圖書論文
1.Crawford, J. M.(1991)。The gastrointestinal tract: malignant tumors。Robbins pathologic basis of disease。WB Saunders Co Philadelphia。  new window
 
 
 
 
第一頁 上一頁 下一頁 最後一頁 top
QR Code
QRCODE

臺灣人文及社會科學引文索引資料庫

目前上線人數：807（臺灣：783，外國：24） ／ 本年度總使用人次：1855660 ／ 訪客人次（自102年09月）：67666190
國家圖書館著作權聲明 Copyright © 2013 All rights reserved.
本館地址: 100201臺北市中山南路20號． 本館地圖及交通資訊．
總機：(02)23619132．最佳瀏覽解析度為1024x768以上